Table 5.
Univariate and multivariate analysis for development of CKD 3 or greater (eGFR <60 mL/min/1.73 m2) and persistence/progression for albuminuria in the patients with type 2 diabetes.
| Development of CKD 3 or greater | ||||||
|---|---|---|---|---|---|---|
|
| ||||||
| Univariate analysis | Multivariate analysis | |||||
|
|
|
|||||
| Log-rank statistics | df | P | HR | 95% CI | P | |
| Sex, male | 2.97 | 1 | 0.085 | - | - | - |
| Age, ≥65 years | 0.21 | 1 | 0.644 | - | - | - |
| BMI, ≥25 kg/m2 | 0.71 | 1 | 0.400 | - | - | - |
| Duration of diabetes, ≥10 years | 5.37 | 1 | 0.020 | 1.28 | 0.55–3.01 | 0.571 |
| HbA1c, ≥7% (53 mmol/mol) | 0.40 | 1 | 0.528 | - | - | - |
| LDC cholesterol, ≥2.6mmol/l | 0.11 | 1 | 0.746 | - | - | - |
| HDL cholesterol, ≤1.0 (M), ≤1.3mmol/l (F) | 3.28 | 1 | 0.070 | 1.98 | 0.73–5.40 | 0.183 |
| Triglycerides, ≥3.0mmol/l | 1.29 | 1 | 0.257 | - | - | - |
| eGFR, <90 mL/min/1.73 m2 | 4.85 | 1 | 0.028 | 2.81 | 1.10–7.17 | 0.030 |
| Antihypetensive medication, yes | 7.25 | 1 | 0.007 | 2.48 | 0.93–6.57 | 0.069 |
| Lipid lowering agents, yes | 2.64 | 1 | 0.105 | - | - | - |
| Urine Clusterin/Cr, pg/mg | 12.77 | 3 | 0.005 | 0.032 | ||
| Q1 | 1.00 | |||||
| Q2 | 3.35 | 0.34–32.83 | 0.299 | |||
| Q3 | 10.10 | 1.18–86.86 | 0.035 | |||
| Q4 | 11.76 | 1.43–96.96 | 0.022 | |||
|
| ||||||
| Persistence/progression for albuminuria | ||||||
|
| ||||||
| Univariate analysis | Multivariate analysis | |||||
|
|
|
|||||
| Log-rank statistics | df | P | HR | 95% CI | P | |
|
| ||||||
| Sex, male | 0.18 | 1 | 0.668 | - | - | - |
| Age, ≥65 years | 2.84 | 1 | 0.092 | 5.78 | 1.28–26.22 | 0.023 |
| BMI, ≥25 kg/m2 | 0.65 | 1 | 0.419 | - | - | - |
| Duration of diabetes, ≥10 years | 6.19 | 1 | 0.013 | 2.29 | 1.01–5.21 | 0.047 |
| HbA1c, ≥7% (53 mmol/mol) | 4.05 | 1 | 0.044 | 1.55 | 0.60–4.01 | 0.362 |
| LDC cholesterol, ≥2.6mmol/l | 1.16 | 1 | 0.281 | - | - | - |
| HDL cholesterol, ≤1.0 (M), ≤1.3mmol/l (F) | 0.76 | 1 | 0.382 | - | - | - |
| Triglycerides, ≥3.0mmol/l | 2.37 | 1 | 0.123 | - | - | - |
| eGFR, <90 mL/min/1.73 m2 | 2.42 | 1 | 0.120 | - | - | - |
| Antihypetensive medication, yes | 0.83 | 1 | 0.361 | - | - | - |
| Lipid lowering agents, yes | 4.54 | 1 | 0.033 | 0.47 | 0.20–1.08 | 0.075 |
| Urine Clusterin/Cr, pg/mg | 10.81 | 3 | 0.013 | 0.032 | ||
| Q1 | 1.00 | |||||
| Q2 | 4.75 | 0.94–23.91 | 0.059 | |||
| Q3 | 9.94 | 2.02–48.87 | 0.005 | |||
| Q4 | 4.73 | 0.95–23.57 | 0.058 | |||
BMI, body mass index; CI, coefficient interval; CKD, chronic kidney disease; Cr, creatinine; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein; Q, quartile.